Hydroxyurea to prevent brain injury in children with sickle cell disease (HU Prevent)—A randomized, placebo‐controlled phase II feasibility/pilot study by Casella, James F., Furstenau, Dana K., Adams, Robert J., Brambilla, Donald J., Lebensburger, Jeffrey D., Fehr, James J., Jordan, Lori C., King, Allison A., Ichord, Rebecca N., McKinstry, Robert C., Kraut, Michael A., Shaw, Dennis W., White, Desiree A., Whyte‐Stewart, Donna A., Avadhani, Radhika, Barron‐Casella, Emily A., Cannon, Alicia D., Eaton, Cyd K., Riekert, Kristin A., Shay, Joanne E., Smith‐Seidel, Cynthia A., Weiss, Diane C., Ostapkovich, Noeleen D., Vermillion, Krista, Treine, Kevin E., Kingsbury, Claire E., Strouse, John J., Thompson, Richard E., Hanley, Daniel F.

Get full text

Developing a risk-based composite neurologic outcome for a trial of hydroxyurea in young children with sickle cell disease by Casella, James F, Adams, Robert J, Brambilla, Donald J, Strouse, John J, Maier, Pia, Dlugash, Rachel, Avadhani, Radhika, Vermillion, Krista, Tonascia, James, Voeks, Jenifer H, Hanley, Daniel F, Thompson, Richard E, Lehmann, Harold P

Get full text

Proteomic discovery in sickle cell disease: Elevated neurogranin levels in children with sickle cell disease by Lance, Eboni I., Faulcon, Lisa M., Fu, Zongming, Yang, Jun, Whyte‐Stewart, Donna, Strouse, John J., Barron‐Casella, Emily, Jones, Kimberly, Van Eyk, Jennifer E., Casella, James F., Everett, Allen D.

Get full text